S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00996047|
Recruitment Status : Completed
First Posted : October 16, 2009
Last Update Posted : March 6, 2015
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at bone marrow and blood samples from patients with leukemia or other hematopoietic cancers.
|Condition or disease||Intervention/treatment|
|Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms||Genetic: cytogenetic analysis Genetic: fluorescence in situ hybridization|
* Maintain and expand a database of cytogenetic information on leukemia patients.
Other objectives as funding permits:
- Determine the frequency and prognostic significance of cytogenetic abnormalities in bone marrow or peripheral blood cells in patients with leukemia prior to treatment and at various times during treatment undergoing treatment on a companion clinical trial.
- Correlate the presence of cytogenetic features with clinical, pathophysiological, cellular, and molecular characteristics in these patients.
- Provide quality control for all Southwest Oncology Group cytogenetic data.
OUTLINE: Bone marrow and/or peripheral blood samples from patients on specific treatment protocols for leukemia are analyzed for cytogenetic abnormalities. Samples from patients with chronic lymphocytic leukemia (CLL) are analyzed for trisomy 12 by fluorescence in situ hybridization and conventional cytogenetics.
PROJECTED ACCRUAL: Approximately 2,500 patients (1,200 with first-line acute myeloid leukemia [AML], 500 with first-line acute lymphoblastic leukemia [ALL], 200 with relapsed AML, 125 with chronic phase chronic myelogenous leukemia [CML], 100 with accelerated phase or blastic phase CML, 250 with hairy cell leukemia, and 125 with relapsed ALL or CLL) will be accrued for this study within 5 years.
|Study Type :||Observational|
|Actual Enrollment :||3341 participants|
|Official Title:||S9007, Cytogenetic Studies in Leukemia Patients|
|Study Start Date :||July 1991|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||January 2012|
- Maintain and expand a database of cytogenetic information on leukemia patients. [ Time Frame: While protocol was open ]
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00996047
|Study Chair:||Elisabeth Paietta, PhD||Our Lady of Mercy Medical Center|